In this episode, Bright and Anousha chat with Carl Schmid, Executive Director of the HIV+Hepatitis Policy Institute, about the financial challenges people living with hepatitis B face in the U.S., including high medication costs, insurance barriers, and the ongoing struggle to access affordable, life-saving treatment.
Note:
Carl also shared an important update that at least one widely used hepatitis B medication is now available through Trump Rx for about $20 per month, offering a potentially more affordable option for some patients.
Podden och tillhörande omslagsbild på den här sidan tillhör
Hepatitis B Foundation. Innehållet i podden är skapat av Hepatitis B Foundation och inte av,
eller tillsammans med, Poddtoppen.